Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill & Intangibles (2016 - 2023)

Historic Goodwill & Intangibles for Sangamo Therapeutics (SGMO) over the last 11 years, with Q1 2023 value amounting to $51.6 million.

  • Sangamo Therapeutics' Goodwill & Intangibles fell 4372.58% to $51.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $51.6 million, marking a year-over-year decrease of 4372.58%. This contributed to the annual value of $88.3 million for FY2022, which is 554.34% down from last year.
  • As of Q1 2023, Sangamo Therapeutics' Goodwill & Intangibles stood at $51.6 million, which was down 4372.58% from $88.3 million recorded in Q4 2022.
  • In the past 5 years, Sangamo Therapeutics' Goodwill & Intangibles ranged from a high of $100.9 million in Q4 2020 and a low of $51.6 million during Q1 2023
  • Moreover, its 5-year median value for Goodwill & Intangibles was $92.5 million (2019), whereas its average is $90.1 million.
  • In the last 5 years, Sangamo Therapeutics' Goodwill & Intangibles soared by 581085.17% in 2019 and then crashed by 4372.58% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Goodwill & Intangibles stood at $92.4 million in 2019, then increased by 9.19% to $100.9 million in 2020, then dropped by 7.4% to $93.5 million in 2021, then dropped by 5.54% to $88.3 million in 2022, then plummeted by 41.6% to $51.6 million in 2023.
  • Its last three reported values are $51.6 million in Q1 2023, $88.3 million for Q4 2022, and $81.0 million during Q3 2022.